ReviewCritical reviews in biomedical engineering2012
Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities.
Review in Critical reviews in biomedical engineering, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 157 citations in OpenAlex.
- Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.Medical oncology (Northwood, London, England) · 2017Trial
- Latest developments in photosensitizers: improving stability, specificity and responsiveness.Future medicinal chemistry · 2025Review
- Green/red fluorescent protein disrupting drugs for real-time permeability tracking in three-dimensional tumor spheroids.Bioengineering & translational medicine · 2025Article
- Advancements in Liposomal Nanomedicines: Innovative Formulations, Therapeutic Applications, and Future Directions in Precision Medicine.International journal of nanomedicine · 2025Review
- Article
- Photodynamic Therapy in the Treatment of Cancer-The Selection of Synthetic Photosensitizers.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Nanomaterials in Drug Delivery: Strengths and Opportunities in Medicine.Molecules (Basel, Switzerland) · 2024Review
- Photosensitizers for Photodynamic Therapy of Brain Cancers-A Review.Brain sciences · 2023Review
- Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Article
- Recent advances of bioresponsive polymeric nanomedicine for cancer therapy.Nano research · 2023Review
- Exosomes-mediated tumor treatment: One body plays multiple roles.Asian journal of pharmaceutical sciences · 2022Review
- Dual Size/Charge-Switchable Nanocatalytic Medicine for Deep Tumor Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Kinetics of Nanomedicine in Tumor Spheroid as anFrontiers in bioengineering and biotechnology · 2021Review
- Article
- Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years.Pharmaceutics · 2020Review
- Anti-VCAM-1 and Anti-IL4Rα Aptamer-Conjugated Super Paramagnetic Iron Oxide Nanoparticles for Enhanced Breast Cancer Diagnosis and Therapy.Molecules (Basel, Switzerland) · 2020Article
- Biomimetic Nanomembranes: An Overview.Biomimetics (Basel, Switzerland) · 2020Review
- A nano-integrated diagnostic and therapeutic platform with oxidation-reduction reactions in tumor microenvironments.Nanoscale advances · 2020Article
- Applications of Surface Modification Technologies in Nanomedicine for Deep Tumor Penetration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Poor penetration of anticancer drags into solid tumors significantly limits their efficacy. This phenomenon has long been observed for small-molecule chemotherapeutics, and it can be even more pronounced for nanoscale therapies. Nanoparticles have enormous potential for the treatment of cancer due to their wide applicability as drug delivery and imaging vehicles and their size-dependent accumulation into solid tumors by the enhanced permeability and retention (EPR) effect. Further, synthetic nanoparticles can be engineered to overcome barriers to drag delivery. Despite their promise for the treatment of cancer, relatively little work has been done to study and improve their ability to diffuse into solid tumors following passive accumulation in the tumor vasculature. In this review, we present the complex issues governing efficient penetration of nanoscale therapies into solid tumors. The current methods available to researchers to study nanoparticle penetration into malignant tumors are described, and the most recent works studying the penetration of nanoscale materials into solid tumors are summarized. We conclude with an overview of the important nanoparticle design parameters governing their tumor penetration, as well as by highlighting critical directions in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.